Company

Share

 

About Us

 

Guanhao Biotech is a company focusing on regenerative medicine industry, expanding its business to life science fields. The company builds bridges to globe-wide high-end technological resources and achievements and keeps investing in the area of biomaterials, stem cells, pharmaceutical industry and advanced medical technologies, resulting in a form of "3+1" branches, namely the material, the cell therapy, the pharmaceutical branches and a tech incubator platform.


The company has established a globally competitive medical technology platform of animal-derived biomaterials in the field of regenerative materials after more than a decade's developing time. Relying on its leading level in the inducible regenerative functional biomaterials, the company has been involved in more than twenty national or local scientific projects and has become the national research center and the industrialization demonstration base in this field. The Regenerative Medical Implanted Machine National Engineering Laboratory and The Regenerative Biological Membrane High Technology Industrialization Demonstration Project have been successively appointed to Guanhao Biotech by The National Development and Innovation Committee. In the present, the company holds hundreds of national or world patents and has marketed original products including NormalGEN dura repair patch, GrandNeuro (Type B) dura repair patch, ThromalGEN (Type P) surgical patch, ThromalGEN (Type B) surgical patch, DermalGEN wound dressing, IREAL breast patch and Youvision Acellular corneal graft. As well as the artificial lens products represented by Zhuhai Xiangle, they can be widely used in neurosurgery, thoracic surgery, ophthalmology, dermatology, orthopaedics, cosmetology and so on.


In the fields of cell and stem cell therapies, the company sets steps in autologous chondrocyte implantation (ACI), immune cell bank in the present, and starts to invest in immune cell therapy R&D. In the stem cell area, the company cooperates with the professor Hongkui Deng's research team from Beijing University and has established the Bei Hao Stem cell and Regenerative Research Institute, aiming to build up a world-class platform in generality key technologies of immune cells and to gather global talents and technologies for translational stem cell R&D.


In the field of pharmaceutical industry,Guangdong Zhonghao Pharmaceutical Co., Ltd. and Beijing Wenfeng Tianji Pharmaceutical Technology Co., Ltd., which are controlled by the company, both of which holds the intellectual property of 1.1 class new drug Benvitimode in great China region. Benvitimode is a non-hormonal small molecule chemical isolated from natural microbial metabolites. The medicine is the world's first; it can be used in the treatment of certain autoimmune diseases, for example, psoriasis (commonly known as “scaly tetter”) and eczema; and it was listed as “The 12th five-year plan” national “major new drug creation” major science and technology projects by National Ministry of Science and Technology. In May 2019, Benvidimod Cream, a class of innovative drug, was approved to be marketed through the priority approval procedure of the State Drug Administration. The product is used locally for the treatment of mild to moderate stable psoriasis vulgaris in adults.


As the branch of technology incubation, In the science and technology incubation sector, Guanhao Science Park initiates the professional innovation incubation mode of "listed company + Incubator + industry fund", strives to build the most professional industry-finance interactive life-health innovation and entrepreneurship Incubation Platform in China, and provides the overall solution of entrepreneurship projects and packaging services of industrialization transformation. In December 2017, Guanhao Science Park was identified as a state-level incubator of science and technology enterprises.
 

In the future, the company will continue to integrate resources around regenerative medicine biological material platform、cell therapy technology platform and pharmaceutical technology platform within the field of regenerative medicine, and to enhance the transformation of industrialization, to make Guanhao Biotech Co., Ltd a first-class provider for products, techniques and services in the field of regenerative medicine industry.
 

SitemapQR code

Copyright 冠昊生物科技股份有限公司. 粵ICP備12069953號
互聯網藥品信息服務資格證書編號:(粵)-非經營性-2016-0297

网上的棋牌是不是假的 双色球开奖官网 郑州股票推荐交流群 上证指数每日行情 河南11选5走势图表 扑克21点玩法规则 安徽快3三同号遗漏 天天彩票app下载 贵州11选5彩票平台 云南时时彩接口 股票分红什么时候到账